Table 3.
First author/Study | n | Place | Primary Endpoint | Phase | STAGE | MAINTENANCE TREATMENT | Patients |
---|---|---|---|---|---|---|---|
Pallis et al 2007 | 41 | Greece | DCR | II | IIIB/IV | gefitinib as salvage treatment | Pretreated platinum- or taxane-based |
Kelly et al 2008 (SWOG S0023) | 243 | USA | - | III | III | gefitinib or placebo | Pretreated concurrent chemoradiotherapy and docetaxel |
Patel et al 2009 | 50 | USA | PFS | II | IIIB/IV nonsquamous | pemetrexed and bevacizumab | Untreated 1st line pemetrexed, carboplatin, and bevacizumab |
Zhang et al 2012 (INFORM; C-TONG 0804) | 296 | China | PFS | III | IIIb or IV | Gefitinib versus placebo | Pretreated 1st-line platinum-based doublet |
Cappuzzo et al 2010 (SATURN; BO18192) | 884 | Italy | PFS | III | advanced | erlotinib | Pretreated 1st line/four cycles of platinum-based chemotherapy |